Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
---|---|---|---|---|---|---|
Income Statement | ||||||
Total Revenue | 208.91M | 208.91M | 196.46M | 262.66M | 224.62M | 176.94M |
Gross Profit | 64.80M | 64.80M | 59.97M | 83.69M | 71.70M | 58.83M |
EBITDA | -1.42M | -2.46M | 4.72M | 28.65M | 19.40M | 7.92M |
Net Income | -1.14M | -1.14M | 61.00K | 22.33M | 17.93M | 1.66M |
Balance Sheet | ||||||
Total Assets | 195.84M | 195.84M | 192.44M | 198.05M | 179.82M | 156.11M |
Cash, Cash Equivalents and Short-Term Investments | 35.90M | 35.90M | 24.26M | 24.98M | 40.49M | 43.32M |
Total Debt | 2.28M | 2.28M | 2.76M | 2.46M | 3.02M | 2.42M |
Total Liabilities | 39.18M | 39.18M | 34.49M | 38.73M | 43.97M | 34.55M |
Stockholders Equity | 156.66M | 156.66M | 157.95M | 159.32M | 135.85M | 121.56M |
Cash Flow | ||||||
Free Cash Flow | 7.74M | 7.74M | 2.48M | -15.58M | -1.21M | -1.80M |
Operating Cash Flow | 10.55M | 10.55M | 6.52M | -8.20M | 1.91M | 832.00K |
Investing Cash Flow | 4.02M | 4.02M | -4.04M | -2.18M | -8.12M | 13.37M |
Financing Cash Flow | -3.25M | -3.25M | -2.90M | 389.00K | -352.00K | -3.01M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
61 Neutral | $35.55B | 8.88 | -11.05% | 1.87% | 8.55% | -8.14% | |
59 Neutral | $139.59M | 303.10 | -0.73% | 2.46% | 6.34% | -31.68% | |
52 Neutral | $345.15M | ― | -173.01% | ― | 13.03% | 77.68% | |
52 Neutral | $247.15M | ― | -8.58% | 6.89% | -5.96% | 49.33% | |
51 Neutral | $86.02M | ― | -15.12% | ― | -7.12% | -11.00% | |
47 Neutral | $243.24M | ― | -24.86% | ― | 2.59% | -48.02% | |
47 Neutral | $85.76M | ― | -48.54% | ― | -41.25% | 47.09% |
On January 24, 2025, Richardson Electronics announced the sale of its International Medical Equipment and Service business assets to DirectMed Imaging for $8.2 million. This strategic move aligns with Richardson’s priorities to support its growing Green Energy Solutions business and involves a 10-year supply agreement with DirectMed, simplifying Richardson’s operations and focusing on higher-growth markets.